Valion Bio, Inc. Increase (Decrease) in Accounts Receivable
Valion Bio, Inc. (VBIO) reported Increase (Decrease) in Accounts Receivable of -$50.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-11-14
- Valion Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $6.00K.
- Valion Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $0.00.
- Valion Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was -$56.00K.
- Valion Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was $55.00K, a 129.17% increase year-over-year.
- Valion Bio, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$105.00K, a 256.72% decline from fiscal 2023.
- Valion Bio, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $67.00K.
- Valion Bio, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$1.00K, a 101.52% decline from fiscal 2021.
- Valion Bio, Inc. increase (decrease) in accounts receivable for fiscal 2021 was $66.00K.
| Period end | Increase (Decrease) in Accounts Receivable 1 month | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.00K derived: sum of 2 quarters · filed 2025-11-14 | -$50.00K 10-Q · filed 2025-11-14 | $5.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$56.00K 10-Q · filed 2025-08-14 | -$1.00K derived: sum of 3 quarters · filed 2025-08-14 | -$8.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2025-03-31 | -$56.00K 10-Q · filed 2025-05-15 | -$1.00K derived: sum of 2 quarters · filed 2025-05-15 | -$8.00K derived: sum of 3 quarters · filed 2025-11-14 | -$61.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $48.00K derived: sum of 2 quarters · filed 2025-11-14 | -$5.00K derived: sum of 3 quarters · filed 2025-11-14 | -$105.00K 10-K · filed 2025-03-21 | ||
| 2024-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$60.00K derived: sum of 2 quarters · filed 2025-11-14 | -$160.00K 10-Q · filed 2025-11-14 | -$136.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$153.00K 10-Q · filed 2025-08-14 | -$129.00K derived: sum of 3 quarters · filed 2025-08-14 | -$11.00K derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$100.00K 10-Q · filed 2025-05-15 | -$76.00K derived: sum of 2 quarters · filed 2025-05-15 | $42.00K derived: sum of 3 quarters · filed 2025-05-15 | -$2.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $142.00K derived: sum of 2 quarters · filed 2025-03-21 | $98.00K derived: sum of 3 quarters · filed 2025-03-21 | $67.00K 10-K · filed 2025-03-21 | ||
| 2023-09-30 | $118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $74.00K derived: sum of 2 quarters · filed 2024-11-14 | $43.00K 10-Q · filed 2024-11-14 | $39.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$75.00K 10-Q · filed 2024-08-14 | -$79.00K derived: sum of 3 quarters · filed 2024-08-14 | |||
| 2023-03-31 | -$31.00K 10-Q · filed 2024-05-15 | -$35.00K derived: sum of 2 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$1.00K 10-K · filed 2024-03-25 | -$4.00K 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $3.00K 10-Q · filed 2023-11-14 | |||||
| 2022-03-31 | $30.00K 10-Q · filed 2023-05-15 | $28.00K derived: sum of 2 quarters · filed 2023-05-15 | $25.00K derived: sum of 3 quarters · filed 2023-05-15 | $63.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2022-01-31 | $30.00K 10-Q · filed 2022-05-16 | |||||
| 2021-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$5.00K derived: sum of 2 quarters · filed 2023-03-31 | $33.00K derived: sum of 3 quarters · filed 2023-03-31 | $66.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $35.00K derived: sum of 2 quarters · filed 2022-11-14 | $68.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $71.00K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $33.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |